Once-monthly paliperidone injection for the treatment of schizophrenia

References

• NasrallahHAThe case for long-acting antipsychotic agents in the post-CATIE eraActa Psychiatr Scand2007115426026717355516
   PubMed Web of Science ®Google Scholar
• TaylorDMYoungCPatelMXProspective 6-month follow-up of patients prescribed risperidone long-acting injection: Factors predicting favourable outcomeInt J Neuropsychopharmacol20069668569416939663
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company LimitedSummary of Product CharacteristicsZypadhera 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection2009 Available at: http://emc.medicines.org.uk/Accessed on Jul 14, 2010
   Google Scholar
• BisharaDTaylorDUpcoming agents for the treatment of schizophrenia. Mechanism of action, efficacy and tolerabilityDrugs200868162269229618973393
   PubMed Web of Science ®Google Scholar
• NasrallahHAAtypical antipsychotic-induced metabolic side effects: Insights from receptor-binding profilesMol Psychiatry2008131273517848919
   PubMed Web of Science ®Google Scholar
• HaddadPMAntipsychotics and diabetes: Review of non-prospective dataBr J Psychiatry Suppl200447S80S8615056599
   PubMedGoogle Scholar
• TaylorDMMcAskillRAtypical antipsychotics and weight gain – a systematic reviewActa Psychiatr Scand2000101641643210868465
   PubMed Web of Science ®Google Scholar
• LeysenJEJanssenPMMegensAASchotteARisperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activityJ Clin Psychiatry199455Suppl5127520908
   PubMed Web of Science ®Google Scholar
• SchotteAJanssenPFGommerenWRisperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor bindingPsychopharmacology (Berl)19961241257738935796
   PubMed Web of Science ®Google Scholar
• van BeijsterveldtLEGeertsRJLeysenJERegional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the ratPsychopharmacology (Berl)1994114153627531352
   PubMed Web of Science ®Google Scholar
• CletonARossenuSCrauwelsHAssessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150 mg EG. A new long-acting injectable antipsychotic, following administration in the deltoid or gluteal musclesPoster presented at American Society for Clinical Pharmacology and TherapeuticsOrlando, FL2008 Apr 2–5
   Google Scholar
• CletonARossenuSHoughDEvaluation of the pharmacokinetic profile of deltoid versus gluteal intramuscular injections of paliperidone palmitate in patients with schizophreniaPoster presented at the American Society for Pharmacology and TherapeuticsOrlando, FL2008 Apr 2–5
   Google Scholar
• JanssenOnce-monthly Invega Sustenna: Paliperidone palmitate extended-release injectable suspension2009 Available at: http://www.invegasustenna.com/invegasustenna/assets/hcp/01PM09110.pdfAccessed on Jul 14, 2010
   Google Scholar
• KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol201013563564719941696
   PubMed Web of Science ®Google Scholar
• SamtaniMNVermeulenAStuyckensKPopulation pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: A novel once-monthly, long-acting formulation of an atypical antipsychoticClin Pharmacokinet200948958560019725593
   PubMed Web of Science ®Google Scholar
• SedkyKNazirRLindenmayerJPLippmanSPaliperidone palmitate: Once monthly treatment option for schizophreniaCurrent Psychiatry Online2010934850
   Google Scholar
• GopalSHoughDWXuHEfficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: A randomized, double-blind, placebo-controlled, dose-response studyInt Clin Psychopharmacol2010410 [Epub ahead of print]
   Web of Science ®Google Scholar
• PandinaGJLindenmayerJPLullJA randomized, placebocontrolled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol201030323524420473057
   PubMed Web of Science ®Google Scholar
• NasrallahHAGopalSGassmann-MayerCEfficacy and safety of three doses of paliperidone palmitate, an investigational longacting injectable antipsychotic in schizophreniaPoster presented at the Institute on Psychiatric Services Annual MeetingChicago, IL2008 Oct 2–5
   Google Scholar
• HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled studySchizophr Res201011623107117
   Web of Science ®Google Scholar
• GopalSVijapurkarULimPMorozovaMEerdekensHoughDA 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophreniaJ Psychopharmacol Online-First78201010.1177/0269881110372817
   Web of Science ®Google Scholar
• FleischhackerWWGopalSSamtaniMOptimization of the dosing strategy for the long-acting injectable antipsychotic paliperidone palmitate: Results of two randomized double-blind studies and population pharmacokinetic simulationsPoster presented at the American Society for Pharmacology and TherapeuticsScottsdale, AZ2008 Dec 7–11
   Google Scholar
• PandinaGLaneRGopalSA randomized, double-blind, comparative study of flexible doses of paliperidone palmitate and risperidone long-acting therapy in patients with schizophreniaPoster presented at the 48th American College of NeuropsychopharmacologyHollywood, FL2009 Dec 6–10
   Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• HaroJMKamathSAOchoaSThe Clinical Global Impression-Schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophreniaActa Psychiatr Scand Suppl2003416162312755850
   PubMedGoogle Scholar
• PatrickDLAdriaenseenIMorosiniPLGagnonDRothmanMReliability, validity and sensitivity to change of the Personal and Social Performance scale in patients with acute schizophreniaPoster presented at Collegium Internationale NeuropsychopharmacologicumChicago, IL2006 Jul 9–13
   Google Scholar
• CitromeLPaliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medicationInt J Clin Pract201064221623919886879
   PubMed Web of Science ®Google Scholar
• HoughDLindenmayerJPGopalSSafety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophreniaProg Neuropsychopharmacol Biol Psychiatry20093361022103119481579
   PubMed Web of Science ®Google Scholar
• CoppolaDLiuYGopalSLong-term safety, tolerability and pharmacokinetics of paliperidone palmitate 234mg (150 mg eq.), the highest marketed dose: A one-year open-label study in patients with schizophreniaPoster presented at the American Society for Pharmacology and TherapeuticsAtlanta, GA2010 Mar 17–30
   Google Scholar
• TaylorDPatonCKapurSThe Maudsley Prescribing Guidelines10th EditionLondonInforma Healthcare2009
   Google Scholar